Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 45, 2012, Pages 18281-18289

  McTigue, Michele ^a   Murray, Brion William ^a   Chen, Jeffrey H ^a   Deng, Ya Li ^a   Solowiej, James ^a   Kania, Robert S ^a  

^a PFIZER INC   (United States)

Author keywords

Axitinib; Pazopanib; Sorafenib; Sunitinib; Tivozanib

Indexed keywords

AXITINIB; BRIVANIB; CEDIRANIB; HYDROGEN; LINIFANIB; PAZOPANIB; SORAFENIB; SUNITINIB; TIVOZANIB; VASCULOTROPIN;

ARTICLE; AUTOPHOSPHORYLATION; CONFORMATION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; UMBILICAL VEIN ENDOTHELIAL CELL;

CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; DISEASE-FREE SURVIVAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; KIDNEY NEOPLASMS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867816311     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1207759109     Document Type: Article

References (42)

1. Albiges L, Salem M, Rini B, Escudier B (2011) Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma. Hematol Oncol Clin North Am 25:813-833.
2. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell cancer (RCC): A Cochrane systematic review of published randomised trials. BJU Int 108:1556-1563.
3. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143.
4. Rini BI, et al. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939.
5. Empfield JR, Leeson PD (2010) Lessons learned from candidate drug attrition. IDrugs 13:869-873.
6. Meanwell NA (2011) Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chem Res Toxicol 24:1420-1456.
7. Stepan AF, et al. (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: A perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345-1410.
8. Price DA, Blagg J, Jones L, Greene N, Wager T (2009) Physicochemical drug properties associated with in vivo toxicological outcomes: A review. Expert Opin Drug Metab Toxicol 5:921-931.
9. Leeson PD, Empfield JR (2010) Reducing the risk of drug attrition associated with physicochemical properties. Annu Rep Med Chem 45:393- 407.
10. Edwards MP, Price DA (2010) Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks. Annu Rep Med Chem 45:381-391.
11. Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD (2003) A comparison of physiochemical property profiles of development and marketed oral drugs. J Med Chem 46:1250-1256. (Pubitemid 36428230)
12. Kania RS (2009) Structure-Based Design and Characterization of Axitinib. Kinase Inhibitor Drugs, Drug Discovery and Development, eds Li R, Stafford JA (Wiley, New York), pp 167-201.
13. Dar ACSK, Shokat KM (2011) The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu Rev Biochem 80:769-795.
14. Wodicka LM, et al. (2010) Activation state-dependent binding of small molecule kinase inhibitors: Structural insights from biochemistry. Chem Biol 17:1241-1249.
15. Solowiej J, et al. (2009) Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 48:7019-7031.
16. Walter M, et al. (2007) The 2.7 A crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol 367:839-847. (Pubitemid 46330380)
17. Mol CD, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c- Kit tyrosine kinase. J Biol Chem 279:31655-31663. (Pubitemid 39037836)
18. Griffith J, et al. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13:169- 178.
19. Gajiwala KS, et al. (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542-1547.
20. Chien E, et al. (2007) US Patent 7,303,893.
21. McTigue MA, et al. (1999) Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: A key enzyme in angiogenesis. Structure 7:319-330. (Pubitemid 29159691)
22. Motzer RJ, et al. (2007) Sunitinib efficacy against advanced renal cell carcinoma. J Urol 178:1883-1887. (Pubitemid 47538608)
23. Card A, et al. (2009) High-throughput biochemical kinase selectivity assays: Panel development and screening applications. J Biomol Screen 14:31-42.
24. Davis MI, et al. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 29:1046-1051.
25. Bender SL, et al. (2004) International Patent WO 2004/092217.
26. Karaman MW, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
27. Alton GR, Lunney EA (2008) Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Expert Opin Drug Discov 3:595-605. (Pubitemid 351890672)
28. Harmange J-C, et al. (2008) Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: Design, synthesis, and evaluation. J Med Chem 51:1649-1667. (Pubitemid 351438848)
29. Motzer RJ, et al. (2011) Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial. J Clin Oncol 29(Suppl):4547.
30. Sternberg CN, et al. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068.
31. Escudier B, et al. (2009) Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318.
32. De Luca A, Normanno N (2010) Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 13:636-645.
33. Rini BI, et al. (2011) Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 17:3841-3849.
34. Morrison JF (1969) Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta 185:269-286.
35. Murphy DJ (2004) Determination of accurate KI values for tight-binding enzyme inhibitors: An in silico study of experimental error and assay design. Anal Biochem 327:61-67.
36. Sportsman JR, Gaudet EA, Boge A (2004) Immobilized metal ion affinity-based fluorescence polarization (IMAP): Advances in kinase screening. Assay Drug Dev Technol 2:205-214. (Pubitemid 38647430)
37. Vonrhein C, et al. (2011) Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr 67:293-302.
38. Brunger AT (1992) X-PLOR Version 3.1. A System for X-Ray Crystallography and NMR (Yale Univ Press, New Haven, CT).
39. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255. (Pubitemid 27235885)
40. Brünger AT, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54:905-921.
41. McRee DE (1992) A visual protein crystallographic software system for X11/Xview. J Mol Graph 10:44-46.
42. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.